Stryker in Kalamazoo Receives FDA Approval for Rear Brain Aneurysm Stent

Stryker, large medical technology company in Kalamazoo, announced on Tuesday that it has received U.S. Food and Drug Administration approval for an expanded indication of its Neuroform Atlas Stent System, becoming the first and only adjunctive stent approved for use in the posterior (back of the brain) circulation.
30
Stryker's new stent
Stryker has received U.S. FDA approval for an expanded use of its Neuroform Atlas Stent System for use for posterior brain circulation. / Image courtesy of Stryker

Stryker, large medical technology company in Kalamazoo, announced on Tuesday that it has received U.S. Food and Drug Administration approval for an expanded indication of its Neuroform Atlas Stent System, becoming the first and only adjunctive stent approved for use in the posterior (back of the brain) circulation.

 Aneurysms in the posterior circulation rupture more frequently and are generally more difficult to treat. With the approval of the Neuroform Atlas adjunctive stent for the posterior circulation, long term treatment is more feasible.

Already approved for use in the anterior circulation, the expanded indication was granted based on clinical trial evidence proving the safety and efficacy of the device. The combined patients from both the anterior and posterior cohorts totaled 298 patients, making it the largest study of its kind.

“The Atlas Posterior PMA trial data shows a compelling advancement in the treatment of wide-neck posterior aneurysms,” says Dr. Sam Zaidat, director of the Neuroscience and Stroke Center at Mercy Health System in Toledo, and co-principal investigator of the U.S. Neuroform Atlas investigational trial.

“Posterior stent assisted coiling with Neuroform Atlas achieved an impressive high rate of complete occlusion in this very challenging location at 76.7 percent. Equally impressive was the 4.3 percent primary safety rate.”

An estimated 6.5 million people in the United States have unruptured brain aneurysms with an average rupture rate of 1 every 18 minutes.  Ruptured brain aneurysms are fatal in roughly 50 percent of cases.

“Complete occlusion, or complete blocking of blood flow, is the gold standard in determining long term aneurysm healing,” says Dr. Brian Jankowitz, director of cerebrovascular surgery at the Cooper Neurological Institute in Camden, N.J.

“With the additional challenges that come with treating posterior circulation aneurysms, we never would have anticipated reaching occlusion rates that rival those found in the anterior circulation. Now with Neuroform Atlas, those same high rates are achievable.”

Stryker’s Neuroform Atlas Stent System is a self-expanding nitinol stent used in conjunction with metal coils to pack weakened blood vessel sacs called aneurysms within the brain. The stent is positioned across the aneurysm neck to hold metal coils in place and occlude the aneurysm.

“The results from the Atlas Posterior PMA trial demonstrate that physicians can now address the more difficult posterior circulation aneurysms, offering hope for better outcomes in that patient population,” says Mark Paul, president of Stryker’s Neurovascular division. “This expanded indication of Neuroform Atlas, as the first and only adjunctive stent for use in the posterior circulation, reflects our ongoing commitment to advancing stroke care for patients with cerebrovascular disease.”

Facebook Comments